TMC Life Sciences Berhad (KLSE:TMCLIFE)

Market Cap	792.56M
Revenue (ttm)	326.25M
Net Income (ttm)	2.21M
Shares Out	1.74B
EPS (ttm)	0.00
PE Ratio	359.11
Forward PE	n/a
Dividend	0.02 (4.87%)
Ex-Dividend Date	Dec 5, 2024

Volume	47,000
Average Volume	104,095
Open	0.4550
Previous Close	0.4650
Day's Range	0.4500 - 0.4550
52-Week Range	0.3650 - 0.7550
Beta	0.43
RSI	53.69
Earnings Date	May 23, 2025

About TMC Life Sciences Berhad

TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara (THKD), a medical bedded center located in Selangor. Its THKD provides women and children health, cancer, orthopedics, ENT, head and neck laser, gastro, hepato, urology, fertility health services. In addition, the company’s reproductive treatment comprises in-vitro fertilisation, preimplantation genetic testing, fertility preservation, laparoscopic surgery, surgical sperm retrieval, and donation...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1994
• Country: Malaysia
• Stock Exchange: Bursa Malaysia
• Ticker Symbol: TMCLIFE

Financial Performance

In 2024, TMC Life Sciences Berhad's revenue was 346.42 million, an increase of 11.19% compared to the previous year's 311.56 million. Earnings were 40.65 million, an increase of 3.54%.